Covaxin safe for children 2-18: Bharat Biotech

Bharat Biotech had conducted studies to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in healthy children and adolescents in the 2-18 age group, a press release from the vaccine maker said.